JP2018527886A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018527886A5 JP2018527886A5 JP2017565108A JP2017565108A JP2018527886A5 JP 2018527886 A5 JP2018527886 A5 JP 2018527886A5 JP 2017565108 A JP2017565108 A JP 2017565108A JP 2017565108 A JP2017565108 A JP 2017565108A JP 2018527886 A5 JP2018527886 A5 JP 2018527886A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- prognosis
- metastasis
- characterization
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000011510 cancer Diseases 0.000 claims 31
- 206010028980 Neoplasm Diseases 0.000 claims 29
- 230000014509 gene expression Effects 0.000 claims 25
- 238000000034 method Methods 0.000 claims 21
- 239000000523 sample Substances 0.000 claims 20
- 206010027476 Metastases Diseases 0.000 claims 18
- 230000009401 metastasis Effects 0.000 claims 18
- 238000012512 characterization method Methods 0.000 claims 15
- 238000004393 prognosis Methods 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 238000010837 poor prognosis Methods 0.000 claims 10
- 229940127089 cytotoxic agent Drugs 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 238000012360 testing method Methods 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 101150028074 2 gene Proteins 0.000 claims 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 4
- 238000003559 RNA-seq method Methods 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 238000004883 computer application Methods 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 238000003860 storage Methods 0.000 claims 3
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 238000000636 Northern blotting Methods 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 229940123237 Taxane Drugs 0.000 claims 2
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims 2
- 229960000853 abiraterone Drugs 0.000 claims 2
- 230000003321 amplification Effects 0.000 claims 2
- 230000003388 anti-hormonal effect Effects 0.000 claims 2
- 229960000997 bicalutamide Drugs 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000011065 in-situ storage Methods 0.000 claims 2
- 238000002493 microarray Methods 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000012188 paraffin wax Substances 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 210000005267 prostate cell Anatomy 0.000 claims 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229960000074 biopharmaceutical Drugs 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 238000004590 computer program Methods 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000002751 oligonucleotide probe Substances 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1510684.2A GB201510684D0 (en) | 2015-06-17 | 2015-06-17 | Gene signatures predictive of metastatic disease |
| GB1510684.2 | 2015-06-17 | ||
| PCT/GB2016/051825 WO2016203262A2 (en) | 2015-06-17 | 2016-06-17 | Gene signatures predictive of metastatic disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018527886A JP2018527886A (ja) | 2018-09-27 |
| JP2018527886A5 true JP2018527886A5 (enExample) | 2019-07-04 |
Family
ID=53784091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017565108A Pending JP2018527886A (ja) | 2015-06-17 | 2016-06-17 | 転移性疾患の予測的遺伝子シグネチャー |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210254166A1 (enExample) |
| EP (1) | EP3310927B1 (enExample) |
| JP (1) | JP2018527886A (enExample) |
| CN (1) | CN108513587A (enExample) |
| CA (1) | CA2989388A1 (enExample) |
| GB (1) | GB201510684D0 (enExample) |
| HK (1) | HK1246367A1 (enExample) |
| WO (1) | WO2016203262A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11341138B2 (en) * | 2017-12-06 | 2022-05-24 | International Business Machines Corporation | Method and system for query performance prediction |
| GB201901439D0 (en) * | 2019-02-01 | 2019-03-27 | Univ London | Method of predicting survival rates for cancer patients |
| GB201903015D0 (en) * | 2019-03-08 | 2019-04-17 | Univ Edinburgh | Macrophage expression in breast cancer |
| GB201903014D0 (en) * | 2019-03-06 | 2019-04-17 | Univ Edinburgh | Macrophage markers in cancer |
| CA3168490A1 (en) * | 2020-01-21 | 2021-07-29 | Miha STAJDOHAR | Evaluating the robustness and transferability of predictive signatures across molecular biomarker datasets |
| EP4133491A1 (en) | 2020-04-09 | 2023-02-15 | Tempus Labs, Inc. | Predicting likelihood and site of metastasis from patient records |
| CN116096899A (zh) | 2020-06-29 | 2023-05-09 | Ionis制药公司 | 调节plp1的化合物和方法 |
| US20230390367A1 (en) * | 2020-10-19 | 2023-12-07 | Temple University - Of The Commonwealth System Of Higher Education | Genetic approach to suppress coronaviruses |
| CN120197220B (zh) * | 2025-05-23 | 2025-08-01 | 华信咨询设计研究院有限公司 | 一种基于数据集中度的数据风险评估方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4437975A (en) | 1977-07-20 | 1984-03-20 | Mobil Oil Corporation | Manufacture of lube base stock oil |
| CA1340843C (en) | 1987-07-31 | 1999-12-07 | J. Lawrence Burg | Selective amplification of target polynucleotide sequences |
| KR0148265B1 (ko) | 1988-12-16 | 1998-10-15 | 에프.지이.엠 헤르만스 | 자가-지속 서열 복제 시스템 |
| US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| EP1474528A4 (en) * | 2000-10-13 | 2006-06-14 | Protein Design Labs Inc | METHODS FOR DIAGNOSING PROSTATE CANCER, COMPOSITIONS AND METHODS FOR SCREENING PROSTATE CANCER MODULATORS |
| WO2004067726A2 (en) | 2003-01-29 | 2004-08-12 | Keck Graduate Institute | Isothermal reactions for the amplification of oligonucleotides |
| EP1604014A4 (en) * | 2003-03-20 | 2008-03-26 | Dana Farber Cancer Inst Inc | GENE EXPRESSION IN BREAST CANCER |
| US7306910B2 (en) * | 2003-04-24 | 2007-12-11 | Veridex, Llc | Breast cancer prognostics |
| AU2005300688B2 (en) | 2004-11-03 | 2012-02-02 | Almac Diagnostics Limited | Transcriptome microarray technology and methods of using the same |
| US20140018249A1 (en) * | 2006-07-26 | 2014-01-16 | Health Discovery Corporation | Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia |
| JP2010535529A (ja) | 2007-08-13 | 2010-11-25 | アルマック ダイアグノスティックス リミテッド | マイクロアレイ製造用３’ベースシークエンシング手法 |
| WO2010068839A2 (en) * | 2008-12-11 | 2010-06-17 | The Regents Of The University Of California | Membrane compositions and methods for making and using them |
| CA2782620A1 (en) * | 2009-12-01 | 2011-06-09 | Compendia Bioscience, Inc. | Classification of cancers |
| EP2709614A4 (en) * | 2011-05-17 | 2015-04-15 | Takeda Pharmaceutical | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER |
| US20150218646A1 (en) * | 2012-07-20 | 2015-08-06 | Diagnocure Inc | Methods, kits and compositions for providing a clinical assessment of prostate cancer |
-
2015
- 2015-06-17 GB GBGB1510684.2A patent/GB201510684D0/en not_active Ceased
-
2016
- 2016-06-17 CA CA2989388A patent/CA2989388A1/en not_active Abandoned
- 2016-06-17 EP EP16731299.0A patent/EP3310927B1/en active Active
- 2016-06-17 WO PCT/GB2016/051825 patent/WO2016203262A2/en not_active Ceased
- 2016-06-17 JP JP2017565108A patent/JP2018527886A/ja active Pending
- 2016-06-17 CN CN201680045157.3A patent/CN108513587A/zh active Pending
- 2016-06-17 US US15/736,667 patent/US20210254166A1/en not_active Abandoned
- 2016-06-17 HK HK18105968.7A patent/HK1246367A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018527886A5 (enExample) | ||
| JP5690588B2 (ja) | 肝細胞癌のサブタイプを決定し、肝癌幹細胞を検出するための方法 | |
| KR101579934B1 (ko) | 직장결장암용 예후 예측 | |
| Yuan et al. | Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients | |
| JP2017507320A5 (enExample) | ||
| JP6144695B2 (ja) | タキサン療法を用いて乳癌を処置する方法 | |
| JP2019516407A5 (enExample) | ||
| JP2019516406A5 (enExample) | ||
| CN104975099A (zh) | Hedgehog抑制剂治疗的生物标志物 | |
| JP2013500001A5 (enExample) | ||
| Eissa et al. | Evaluation of urinary miRNA-96 as a potential biomarker for bladder cancer diagnosis | |
| ES2963390T3 (es) | Método para predecir la eficacia de la quimioterapia en pacientes con cáncer de mama | |
| JP7235508B2 (ja) | Ｐｄ－１免疫チェックポイント阻害剤による治療に対するがんの感受性を予測する方法 | |
| US10036070B2 (en) | Methods and means for molecular classification of colorectal cancers | |
| CN110055327B (zh) | 用于预测癌症免疫治疗效果的内皮细胞标记物与试剂盒 | |
| Ibusuki et al. | Establishment of a standardized gene-expression analysis system using formalin-fixed, paraffin-embedded, breast cancer specimens | |
| CA2989480C (en) | Kit and method for the diagnosis/prognosis of idiopathic scoliosis | |
| WO2018187624A1 (en) | Methods of detecting lung cancer | |
| Sippl et al. | The influence of distinct regulatory miRNAs of the p15/p16/RB1/E2F pathway on the clinical progression of glioblastoma multiforme | |
| US20210262036A1 (en) | Biomarker for prognosis of colorectal cancer | |
| CN102361990A (zh) | 通过监测两种基因的表达的乳腺癌患者的预后 | |
| JP2024170603A (ja) | 免疫チェックポイント阻害療法からの利益を予測する方法 | |
| CN111315897B (zh) | 用于黑素瘤检测的方法 | |
| KR101381894B1 (ko) | 위암의 림프절 전이 진단 마커로서의 혈청 ｍｉＲＮＡ | |
| CN112813167B (zh) | 标志物linc01977及其应用 |